Skip to main content
. 2020 Jun 3;7(13):2000487. doi: 10.1002/advs.202000487

Scheme 1.

Scheme 1

Schematic illustration of HO1‐inhibiting hybrid nanoparticle for chemo‐and immuno‐combination therapy in acute myeloid leukemia (AML). The hNP is actively targeted to AML cells by sFVA‐modification and passively targeted to LAM cells by negatively charged surface and phagocytic uptake.